Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Inclusion criteria

• ✓. Is a male or nonpregnant female 18 to 49 years of age, inclusive, on Day 1 (first vaccination).
• ✓. Will avoid nonstudy vaccinations until 21 days after the last vaccination.
• ✓. Provides written informed consent prior to the initiation of any study-related procedures.
• ✓. Has a stable health status, as established by physical examination, vital sign measurements, and medical history.
• ✓. Has access to a consistent and reliable means of telephone contact, which may be in the home, workplace, or by personal mobile electronic device.
• ✓. Is able to understand and comply with planned study procedures.
• ✓. Lives a reasonable distance from the site to be able to travel to and from the site for follow-up visits and agrees to go to the site for evaluation in the case of an adverse event.
• ✓. Agrees to stay in contact with the site for the duration of the study, has no current plans to move from the study area, and provides updated contact information as necessary.

Exclusion criteria